RhumbLine Advisers
SGMT icon

RhumbLine Advisers’s Sagimet Biosciences SGMT Stock Holding History

RhumbLine Advisers’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,111
Closed -$20.9K – 4316
2024
Q2 		$20.9K Sell
6,111
-6,706
-52% -$30.8K ﹤0.01% 3865
2024
Q1 		$69.5K Buy
12,817
+7,513
+142% +$54K ﹤0.01% 3549
2023
Q4 		$28.7K Sell
5,304
-186
-3% -$877 ﹤0.01% 3722
2023
Q3 		$48.3K Buy
+5,490
New +$73.1K ﹤0.01% 3648

Other funds holding SGMT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

RhumbLine Advisers's SGMT Position: Q3 2024 in Review

RhumbLine Advisers sold out of Sagimet Biosciences (SGMT) in Q3 2024, closing a stake of 6,111 shares — an estimated $20.9K sold.

RhumbLine Advisers first reported a position in SGMT in Q3 2023 and held it in 4 quarters. The position peaked at $69.5K in Q1 2024. 63 funds tracked by Wall St. Rank hold SGMT as of Q3 2024.

  • RhumbLine Advisers reported no remaining Sagimet Biosciences position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 6,111 Sagimet Biosciences shares in Q3 2024, an estimated $20.9K.
  • RhumbLine Advisers first reported a position in Sagimet Biosciences in Q3 2023 and held it in 4 quarters.
  • RhumbLine Advisers's Sagimet Biosciences position peaked at $69.5K in Q1 2024.
  • 63 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.